Dual VEGFR-2 and EGFR T790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis
Future Medicinal Chemistry · 2025
DOI: 10.1080/17568919.2025.2453409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2025. Verfasst von Marwa Alsulaimany und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, ErbB Receptors, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
New phenyldiazene scaffold-linked heterocyclic pyrazole, pyrimidinone, pyrimidinthione, and/or triazine rings have been developed and synthesized.Methods & results Cytotoxicity of our derivatives was estimated on four cancer and VERO normal cell lines targeting EGFRT790M (epidermal growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) enzymes. Our new derivatives selectively inhibited both VEGFR-2 and EGFR as they have the essential structural requirements for inhibitors of both receptors. Derivative 14 was the most active on A549, HCT116, HepG2, and MCF-7 cancers with half-maximal inhibitory concentration (IC50) = 5.50, 9.77, 7.12, and 7.85 µM respectively. The assessed derivatives 5, 7, 8, 9, 10, 12 and 14 showed IC50 = 54.40–62.60 μM against normal VERO (normal kidney) cells with low toxicity. In addition, derivatives 14, 8, 10, 7 and 9 were discovered to be very good active inhibitors of VEGFR-2 at IC50 values of 1.15, 1.35, 140, 1.78 and 1.90 µM, respectively. Furthermore, derivatives 14, 10, 8, and 9 strongly repressed EGFRT790M with IC50 = 0.28, 0.33, 0.35, and 0.50 µM correspondingly. Additionally, the highly active compounds 8, 10, and 14 showed good ADMET profile.
Conclusion
Our derivatives could be considered as anticancer agents with dual VEGFR-2 and EGFRT790M inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
- Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
- Department of Chemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
- Basic & Medical Sciences Department, Faculty of Dentistry, Alryada University for Science & Technology, Sadat City, Egypt.
- Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
- Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
ORCID-Profile: Khaled El-Adl
Zitieren
APA
Alsulaimany, M., Aljohani, A. K. B., Abd El-Sattar, N. E. A., Almadani, S. A., Alatawi, O. M., Alharbi, H. Y., Aljohani, M. S., Al-Shareef, A. H., Alghamdi, R., Tayeb, S. M., Keshek, D. E., El-Adl, K., & Anwer, K. E. (2025). Dual VEGFR-2 and EGFR T790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2025.2453409
Vancouver
Alsulaimany M, Aljohani AKB, Abd El-Sattar NEA, Almadani SA, Alatawi OM, Alharbi HY, et al. Dual VEGFR-2 and EGFR T790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis. Future Medicinal Chemistry. 2025. doi:10.1080/17568919.2025.2453409
BibTeX
@article{Alsulaimany2025,
author = {Alsulaimany, Marwa and Aljohani, Ahmed K B and Abd El-Sattar, Nour E A and Almadani, Sara A and Alatawi, Omar M and Alharbi, Hussam Y and Aljohani, Majed S and Al-Shareef, Adel H and Alghamdi, Read and Tayeb, Saeed M and Keshek, Doaa E and El-Adl, Khaled and Anwer, Kurls E},
title = {Dual VEGFR-2 and EGFR T790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis},
journal = {Future Medicinal Chemistry},
year = {2025},
doi = {10.1080/17568919.2025.2453409}
}
EUVIMED